Administration of a Molecular Complex of Resins, Polysaccharides and Polyphenols in Irritable Bowel Syndrome.

Inclusion Criteria:

• 1. Male or female patients aged 18 to 75 years (inclusive);
• 2. Diagnosis of IBS according to ROME IV criteria (Appendix 3);
• 3. Abdominal pain score ≥ 4 on a 11-point NRS, on at least 2 days of the 14 days priorto the baseline visit and on at least 2 days of the last 14 days of the washoutperiod, and pain score not > 8 in more than 7 days of each of the two above-mentionedperiods;
• 4. Signed Informed Consent;
• 5. Patients' ability to comply with the study procedures;
• 6. Stable diet in the two months prior to the screening visit;
• 7. *Negative colonoscopy, defined as the absence of clinically relevant changes or ofchanges nonetheless relevant in relation to study participation risk, performed duringthe run-in period, unless:
• a colonoscopy was performed within the previous 5 years and was negative asintended above, or, if more than one was performed within the previous 5 years,the last being negative as intended above;
• the symptoms, if any, for which the last colonoscopy was performed, have remainedunchanged;
• 8. Postmenopausal female patients, i.e., females who have not had a menstrual periodfor at least 12 months or women who have undergone surgical sterilisation (tuballigation or ovary removal). If not, women of childbearing potential must followreliable contraceptive treatment.
• Inclusion criteria applicable only for patients > 50 years of age

Exclusion Criteria:

• 1. Patients taking treatments that may significantly affect the efficacy outcomesmeasures, such as: probiotics and prebiotics (unless contained in milk-derived foodssuch as yogurt and cheese); drugs with adsorbent/sequestrant properties such asdiosmectite; 5-HT3 receptor antagonist drugs, e.g. ondasetron; drugs that modifygastro-intestinal motility, e.g. "final" anti-cholinergic agents such as loperamide,or cholinergic agents; laxatives and faecal softeners) unless they have been taken ata stable dose for at least four weeks prior to the screening visit.
• 2. Patients taking tricyclic antidepressants within six months prior to the screeningvisit;
• 3. Patients taking opioid-containing analgesics within one month prior to thescreening visit;
• 4. Patients taking antibiotics within one month prior to the screening visit;
• 5. Patients with relevant organic, systemic or metabolic disease, or laboratorychanges, that are deemed significant based on specific ranges of normality;
• 6. Patients with organic bowel diseases;
• 7. Patients with unstable psychiatric conditions;
• 8. Patients who have undergone major abdominal surgery, except appendectomy;
• 9. Known hypersensitivity to one or more of the components of the products.
• 10.Women with known or planned pregnancy or breastfeeding;
• 11.Patients with malignancies of any type, or with a history of prior malignancies,except for patients with a history of extra-intestinal malignancies that have beensurgically removed and have not relapsed within the five years prior to participation.